Abstract
Development of a water-soluble prodrug of doxorubicin-formaldehyde conjugate, a labile, active metabolite of doxorubicin, is described. The lead compound is the doxorubicin-salicylamide N-Mannich base, N-(2-hydroxybenzamidomethyl)-doxorubicin (doxsaliform), prepared in 72% yield from reaction of salicylamide with doxorubicin in the presence of formaldehyde. Doxsaliform releases doxorubicin-formaldehyde conjugate under physiological conditions with a half-life of 57 min. The stability of the prodrug is augmented both by salt formation in acidic media and by covalent modification of the 2-hydroxyl of the salicylamide moiety. Doxsaliform is 4 fold more active than doxorubicin against MCF-7 breast and PC-3 prostate cancer cell lines and 10 fold more active against the doxorubicin resistant MCF-7 / ADR cell line.
Keywords: doxorubicin, formaldehyde, prodrug, salicylamide, trigger
Letters in Drug Design & Discovery
Title: Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Volume: 1 Issue: 3
Author(s): P. S. Cogan, C. R. Fowler, G. C. Post and T. H. Koch
Affiliation:
Keywords: doxorubicin, formaldehyde, prodrug, salicylamide, trigger
Abstract: Development of a water-soluble prodrug of doxorubicin-formaldehyde conjugate, a labile, active metabolite of doxorubicin, is described. The lead compound is the doxorubicin-salicylamide N-Mannich base, N-(2-hydroxybenzamidomethyl)-doxorubicin (doxsaliform), prepared in 72% yield from reaction of salicylamide with doxorubicin in the presence of formaldehyde. Doxsaliform releases doxorubicin-formaldehyde conjugate under physiological conditions with a half-life of 57 min. The stability of the prodrug is augmented both by salt formation in acidic media and by covalent modification of the 2-hydroxyl of the salicylamide moiety. Doxsaliform is 4 fold more active than doxorubicin against MCF-7 breast and PC-3 prostate cancer cell lines and 10 fold more active against the doxorubicin resistant MCF-7 / ADR cell line.
Export Options
About this article
Cite this article as:
Cogan S. P., Fowler R. C., Post C. G. and Koch H. T., Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043399000
DOI https://dx.doi.org/10.2174/1570180043399000 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Serenoa Repens, Lycopene and Selenium: A Triple Therapeutic Approach to Manage Benign Prostatic Hyperplasia
Current Medicinal Chemistry Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery Pharmaceutical Nanotechnology United States Patent Watch (April – June 2015)
Pharmaceutical Nanotechnology Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Engineered Gold Nanoshells Killing Tumor Cells: New Perspectives
Current Pharmaceutical Design A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies
Anti-Cancer Agents in Medicinal Chemistry